Physician profile
Muhammad M Alam
NPI 1417906835
$114,032.10
in general payments reported to CMS, 2019-2025
73 companies · $8,619 in 2025
The $8,619 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68K · 2020: $15K · 2021: $345 · 2022: $6,735 · 2023: $11K · 2024: $5,096 · 2025: $8,619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $12K · Food and Beverage: $9,354 · Travel and Lodging: $1,240 · Long Term Medical Supply Or Device Loan: $1,080 · Honoraria: $360 · Education: $311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $11,885.50 |
| Food and Beverage | $9,354.44 |
| Travel and Lodging | $1,239.73 |
| Long Term Medical Supply Or Device Loan | $1,080.33 |
| Honoraria | $360.00 |
| Education | $311.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $54,666.19 | 2019-2023 | Lumakras |
| E.R. Squibb & Sons, L.L.C. | $27,366.17 | 2019-2025 | Opdivo, Opdualag |
| Eli Lilly and Company | $5,187.10 | 2019 | |
| Abbvie INC. | $3,883.90 | 2019-2025 | |
| Celgene Corporation | $3,166.79 | 2019-2025 | Reblozyl, Opdivo, Opdualag |
| Glaxosmithkline, LLC. | $2,451.63 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Novartis Pharmaceuticals Corporation | $2,450.43 | 2019-2025 | |
| Pfizer INC. | $2,283.00 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,259.28 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $1,051.64 | 2019-2025 | |
| Genzyme Corporation | $956.36 | 2019-2025 | |
| Daiichi Sankyo INC. | $780.88 | 2019-2025 | Enhertu, Datroway, Injectafer |
| Janssen Biotech, INC. | $684.71 | 2019-2025 | Erleada, Darzalex, Carvykti |
| Astellas Pharma US INC | $613.20 | 2019-2025 | Vyloy, Xospata, Xtandi |
| Lilly USA, LLC | $542.56 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $512.82 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Exelixis INC. | $442.70 | 2019-2025 | Cabometyx |
| Incyte Corporation | $364.59 | 2019-2025 | Monjuvi, Jakafi, Zynyz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $352.29 | 2019-2025 | Gilotrif |
| Octapharma USA, INC. | $337.48 | 2019-2025 | Octagam Immune Globulin (Human) |
| Aveo Pharmaceuticals, INC. | $310.64 | 2022-2025 | Fotivda |
| Genentech USA, INC. | $276.90 | 2019-2025 | Polivy, Tecentriq, Phesgo |
| Takeda Pharmaceuticals U.S.A., INC. | $276.65 | 2020-2025 | Alunbrig, Iclusig, Ninlaro |
| Alexion Pharmaceuticals, INC. | $229.29 | 2019-2025 | Ultomiris |
| Sobi, INC | $226.82 | 2023-2025 | |
| Seagen INC. | $216.28 | 2019-2025 | |
| Eisai INC. | $213.11 | 2019-2025 | |
| Array Biopharma INC | $212.98 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Pharmaessentia USA Corporation | $188.91 | 2023-2025 | Besremi |
| Regeneron Healthcare Solutions, INC. | $185.17 | 2019-2025 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $179.08 | 2019-2022 | |
| Tesaro, INC. | $152.34 | 2019 | |
| Gilead Sciences, INC. | $152.31 | 2019-2025 | Trodelvy |
| Stemline Therapeutics INC. | $149.84 | 2019-2025 | Orserdu |
| Tersera Therapeutics LLC | $143.83 | 2019-2025 | Zoladex, Quzyttir |
| Novo Nordisk INC | $124.85 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $120.24 | 2019-2025 | Onivyde |
| Springworks Therapeutics, INC. | $106.57 | 2024-2025 | Ogsiveo |
| Caris Mpi, INC. | $94.80 | 2025 | Mi Cancer Seek |
| Puma Biotechnology, INC. | $67.39 | 2019-2025 | |
| Beigene USA, INC. | $65.65 | 2024 | Brukinsa |
| Dova Pharmaceuticals | $58.34 | 2019 | |
| Tempus Ai, INC | $57.27 | 2024-2025 | Xt Cdx |
| Agios Pharmaceuticals, INC. | $50.99 | 2024-2025 | Pyrukynd |
| Tactile Systems Technology INC | $49.15 | 2025 | Flexitouch Plus, Nimbl |
| Taiho Oncology, INC. | $48.29 | 2024 | |
| Karyopharm Therapeutics INC. | $47.63 | 2020-2023 | Xpovio |
| Geron Corporation | $47.36 | 2024-2025 | Rytelo |
| Verity Pharmaceuticals INC. | $47.27 | 2025 | Trelstar |
| Servier Pharmaceuticals LLC | $41.02 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $40.02 | 2024 | Orgovyx |
| Apellis Pharmaceuticals, INC. | $38.19 | 2024 | Empaveli |
| Janssen Pharmaceuticals, INC | $38.07 | 2019 | |
| Myriad Genetic Laboratories, INC. | $37.01 | 2024 | Myrisk |
| Medtronic, INC. | $35.25 | 2024 | Osteocool Rf Ablation System |
| Immunocore Limited | $34.44 | 2024 | Kimmtrak |
| Kyowa Kirin, INC. | $31.75 | 2019-2021 | |
| Iovance Biotherapeutics, INC. | $27.86 | 2025 | Amtagvi |
| Rigel Pharmaceuticals, INC. | $25.88 | 2024 | Rezlidhia, Tavalisse |
| Accord Healthcare, INC. | $24.29 | 2024 | |
| Shire North American Group INC | $22.92 | 2019 | |
| Shield Therapeutics INC | $22.73 | 2025 | |
| Biomarin Pharmaceutical INC. | $22.59 | 2024 | Roctavian |
| Deciphera Pharmaceuticals INC. | $20.04 | 2024 | Qinlock |
| Lexicon Pharmaceuticals, INC. | $18.71 | 2019 | |
| Adc Therapeutics America, INC. | $18.40 | 2025 | |
| Amneal Pharmaceuticals LLC | $17.33 | 2025 | Alymsys |
| Immunogen, INC. | $16.76 | 2023 | Elahere |
| Eusa Pharma (US) LLC | $16.28 | 2019 | |
| Novocure INC. | $15.09 | 2025 | Optune Lua (Novottf-200t) |
| Recordati_rare_diseases_inc. | $13.80 | 2025 | Sylvant |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Alam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.